Biotech Breakthroughs Send Roivant and Pharvaris to All‑Time Highs

It’s not every day that you see two biotech names jump to fresh all‑time highs on a single morning, but that’s exactly what happened today. Roivant Sciences (ROIV) and Pharvaris (PHVS) both unveiled data that made investors sit up straight.

Roivant’s experimental lung‑disease compound, Mosliciguat, wrapped up a Phase 2 trial with 135 patients. The numbers were eye‑catching: pulmonary vascular resistance dropped by a whopping 56.3 % versus placebo after 16 weeks. On top of that, trial participants walked an extra 35 meters in a six‑minute walk test and saw NT‑proBNP – a heart‑stress marker – cut by more than half. H.C. Wainwright quickly lifted its price target to $47 (up from $41) and stuck with a “Buy” rating, calling the results the strongest reduction ever seen in a randomized pulmonary‑hypertension study.

The market reacted in kind. Roivant’s shares surged over 20 % by the time this piece went live, pushing the stock up nearly 92 % year‑to‑date. Retail chatter on Stocktwits flipped from bearish to “extremely bullish,” with message traffic spiking dramatically.

Across the hall, Pharvaris was celebrating its own win. The company’s oral drug Deucrictibant XR cleared a pivotal Phase 3 trial aimed at preventing hereditary angioedema (HAE) attacks. Patients on the once‑daily regimen saw an 83 % drop in attacks compared with placebo; for those with Type 1 or Type 2 HAE, the reduction jumped to 87 %. The study also met every secondary efficacy endpoint and reported a clean safety profile.

Pharvaris didn’t waste any time translating the data into market optimism. The stock climbed nearly 8 % in early trading, and overall it’s up more than 43 % for the year. Stocktwits users switched their sentiment to “extremely bullish” with a flurry of messages buzzing about the upcoming regulatory filings slated for early 2027, including an FDA submission.

Both companies say the data will be the backbone of upcoming regulatory applications, and investors seem to agree that the upside potential is hard to ignore. As always, biotech is a roller‑coaster, but today the ride was decidedly upward.